That research will be crucial: An earlier effort by another company, Pathway Genomics, to create a «
liquid biopsy» for cancer was greeted in September by a stern letter from the Food and Drug Administration (FDA) warning that the agency had «not found any published evidence that this test or any
similar test has been clinically validated as a screening tool for early detection of cancer in high risk individuals.»